MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

Julia R Dahlqvist; Per Widholm; Olof Dahlqvist Leinhard; John Vissing

doi:10.1002/ana.25804

MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

Julia R Dahlqvist, Per Widholm, Olof Dahlqvist Leinhard, John Vissing

Department of Neurology

54 Citations (Scopus)

Abstract

There is an unmet need to identify biomarkers sensitive to change in rare, slowly progressive neuromuscular diseases. Quantitative magnetic resonance imaging (MRI) of muscle may offer this opportunity, as it is noninvasive and can be carried out almost independent of patient cooperation and disease severity. Muscle fat content correlates with muscle function in neuromuscular diseases, and changes in fat content precede changes in function, which suggests that muscle MRI is a strong biomarker candidate to predict prognosis and treatment efficacy. In this paper, we review the evidence suggesting that muscle MRI may be an important biomarker for diagnosis and to monitor change in disease severity. ANN NEUROL 2020;88:669-681.

Original language	English
Journal	Annals of Neurology
Volume	88
Issue number	4
Pages (from-to)	669-681
Number of pages	13
ISSN	0364-5134
DOIs	https://doi.org/10.1002/ana.25804
Publication status	Published - Oct 2020

Access to Document

10.1002/ana.25804

Cite this

@article{7e9c5b29717042a380fcc17785028a55,

title = "MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy",

abstract = "There is an unmet need to identify biomarkers sensitive to change in rare, slowly progressive neuromuscular diseases. Quantitative magnetic resonance imaging (MRI) of muscle may offer this opportunity, as it is noninvasive and can be carried out almost independent of patient cooperation and disease severity. Muscle fat content correlates with muscle function in neuromuscular diseases, and changes in fat content precede changes in function, which suggests that muscle MRI is a strong biomarker candidate to predict prognosis and treatment efficacy. In this paper, we review the evidence suggesting that muscle MRI may be an important biomarker for diagnosis and to monitor change in disease severity. ANN NEUROL 2020;88:669-681.",

author = "Dahlqvist, {Julia R} and Per Widholm and Leinhard, {Olof Dahlqvist} and John Vissing",

note = "{\textcopyright} 2020 American Neurological Association.",

year = "2020",

month = oct,

doi = "10.1002/ana.25804",

language = "English",

volume = "88",

pages = "669--681",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",

number = "4",

}

TY - JOUR

T1 - MRI in Neuromuscular Diseases

T2 - An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

AU - Dahlqvist, Julia R

AU - Widholm, Per

AU - Leinhard, Olof Dahlqvist

AU - Vissing, John

PY - 2020/10

Y1 - 2020/10

N2 - There is an unmet need to identify biomarkers sensitive to change in rare, slowly progressive neuromuscular diseases. Quantitative magnetic resonance imaging (MRI) of muscle may offer this opportunity, as it is noninvasive and can be carried out almost independent of patient cooperation and disease severity. Muscle fat content correlates with muscle function in neuromuscular diseases, and changes in fat content precede changes in function, which suggests that muscle MRI is a strong biomarker candidate to predict prognosis and treatment efficacy. In this paper, we review the evidence suggesting that muscle MRI may be an important biomarker for diagnosis and to monitor change in disease severity. ANN NEUROL 2020;88:669-681.

AB - There is an unmet need to identify biomarkers sensitive to change in rare, slowly progressive neuromuscular diseases. Quantitative magnetic resonance imaging (MRI) of muscle may offer this opportunity, as it is noninvasive and can be carried out almost independent of patient cooperation and disease severity. Muscle fat content correlates with muscle function in neuromuscular diseases, and changes in fat content precede changes in function, which suggests that muscle MRI is a strong biomarker candidate to predict prognosis and treatment efficacy. In this paper, we review the evidence suggesting that muscle MRI may be an important biomarker for diagnosis and to monitor change in disease severity. ANN NEUROL 2020;88:669-681.

UR - http://www.scopus.com/inward/record.url?scp=85087296458&partnerID=8YFLogxK

U2 - 10.1002/ana.25804

DO - 10.1002/ana.25804

M3 - Review

C2 - 32495452

SN - 0364-5134

VL - 88

SP - 669

EP - 681

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this